Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy

NCT02573636 is registered in ClinicalTrials.gov with Sir Mortimer B. Davis - Jewish General Hospital as lead sponsor.

NCT NCT02573636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02573636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Phase
Observational
Overall status
Recruiting
Start date
March 31, 2016
Completion date
March 31, 2027
Enrollment
208 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer